A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults (NCT05371080)
A Phase 3b, Open-label, Multi-country, Multi-centre, Long-term Follow-up Study of ZOSTER-049 (Follow-up of ZOSTER-006/022 Studies) to Assess the Prophylactic Efficacy, Safety and Persistence of Immune Response of a Herpes Zoster Subunit Vaccine and Assessment of Persistence of Immune Response and Safety of 1 or 2 Additional Doses Administered in ZOSTER-049 in 2 Subgroups of Older Adults
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the current ZOSTER-101 long-term follow-up (LTFU) study of ZOSTER-049 (NCT02723773) study, an extension of ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies, is to assess the long-term vaccine efficacy (VE) against Herpes Zoster (HZ) (approximately 11-15 years post primary vaccination in ZOSTER-006/022 studies), persistence of immunogenicity and safety of GSK's Herpes Zoster subunit (HZ/su) vaccine in older adults. The persistence of immunogenicity and safety of 1 or 2 additional doses (0, 2-month schedule) of HZ/su vaccine administered to a small group of participants in ZOSTER-049 study (approximately 5 years after the initial vaccination in ZOSTER-006/022 studies) will also be assessed.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Phoenix, Arizona
Age range: 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (107 Sites)
Showing the first 25 of 107 sites.
- GSK Investigational Site — Phoenix, Arizona
- GSK Investigational Site — Elkridge, Maryland
- GSK Investigational Site — Charlotte, North Carolina
- GSK Investigational Site — Hickory, North Carolina
- GSK Investigational Site — Pittsburgh, Pennsylvania
- GSK Investigational Site — Bristol, Tennessee
- GSK Investigational Site — San Antonio, Texas
- GSK Investigational Site — Salt Lake City, Utah
- GSK Investigational Site — Warrawong, New South Wales
- GSK Investigational Site — Westmead, New South Wales
- GSK Investigational Site — Geelong, Victoria
- GSK Investigational Site — Belo Horizonte, Minas Gerais
- GSK Investigational Site — Curitiba, Paraná
- GSK Investigational Site — São Paulo,
- GSK Investigational Site — São Paulo,
- GSK Investigational Site — Vancouver, British Columbia
- GSK Investigational Site — Victoria, British Columbia
- GSK Investigational Site — Halifax, Nova Scotia
- GSK Investigational Site — Truro, Nova Scotia
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Mirabel, Quebec
- GSK Investigational Site — Québec, Quebec
- GSK Investigational Site — Québec, Quebec
- GSK Investigational Site — Sherbrooke, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Herpes Zoster
- Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older — Tempe, Arizona
- Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions — Canton, Massachusetts
- Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population — Bethesda, Maryland
Explore by condition: All Herpes Zoster clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.